Una de Gato (Uncaria guianensis)
What Is Una de Gato?
Una de Gato is catalogued in the Materia Medica under the binomial Uncaria guianensis, a plant of the Rubiaceae family, native to the Amazon rainforest and Southeast Asia. The material in circulation is inner bark, root — an underground part, harvested once the plant has drawn its reserves down. Most people search for it simply as Una de Gato; suppliers, pharmacopoeias and interaction databases list it as Uncaria guianensis, and matching the two is the first step in identifying what is actually in a product. In the hand it reads as woody-bitter, dry bark astringency — a practical marker of freshness and correct identification.
The written history of Una de Gato begins with household and practitioner use — recipes, harvesting notes and cautions passed between regions — and only much later with laboratory description of what the inner bark, root contains. Beyond its practical use it carries cultural associations — amazonian vine of persistence and gradual repair.
Today most searches for Una de Gato come from people reading about gut health, pain relief and joint health, or checking how it sits alongside a medication they already take. The use most often documented in the literature is reduced osteoarthritis knee pain in a controlled trial, followed by quinovic acid glycosides inhibit TNF-alpha production.
How Does Una de Gato Work?
Una de Gato is not a single active substance. Its chemistry is a mixture, and the fractions that researchers isolate most often are Alkaloids. Alkaloids is the fraction most often standardised in extracts, associated in the literature with bioactive nitrogen-containing compounds.
Traditional practice described Una de Gato in terms of taste, warmth and preparation rather than molecules — a working vocabulary that predicted which extractions were worth making long before any compound was isolated.
The research base is developing: there are human trials, though sample sizes and designs vary, and this profile cites 1 source. Reported findings centre on contains quinovic acid glycosides and lower oxindole alkaloid levels than U. Where research exists, it examines reduced osteoarthritis knee pain in a controlled trial, quinovic acid glycosides inhibit TNF-alpha production and Traditional Amazonian anti-inflammatory for joints and gut. These are areas of study, not established outcomes, and results differ by preparation and dose.
How the plant is prepared changes what you actually get. Its constituents move readily into water and alcohol — so a preparation made in another medium will not carry the same fraction of the plant, which is why traditional recipes specify one over another.
The reason Una de Gato is treated as its own entry rather than a substitute for a related plant is proportion: related species share several of these compound classes, but not in the same ratio or concentration.
Because these constituents are processed by the same pathways that handle many medicines, Una de Gato is documented as interacting with immunosuppressants, antihypertensives and cyp3a4 substrates. That is a question of shared metabolism rather than of potency, and it is the main reason the plant is listed in interaction references at all.
Dose, plant part and growing conditions all shift the constituent profile, so two products carrying the name Una de Gato can differ substantially; this is why reference entries specify inner bark, root and, where they exist, standardisation markers.